Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does “folie à deux” mean?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dig into what was an abysmal month for biotech on Wall Street and pick apart whether better days might be ahead. Then, Kaiser Health News senior correspondent Liz Szabo joins us to talk about the financial toxicity that cancer patients face for pricey tests and targeted treatments. And STAT deputy multimedia and creative director Alissa Ambrose talks about her experience with postpartum depression, an underdiscussed condition that affects about 15 percent of mothers who have recently given birth. Finally, we touch on pharmaceutical tourism to Mexico, the latest biopharma prison sentencing, and some questionable calls from Celgene CEOs new and old.

For more on what we cover, here’s more on biotech’s malaise; here’s the story on the cost of precision medicine; and here’s Alissa’s essay on postpartum depression.

advertisement

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email readoutloud@statnews.com.

advertisement


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at marketing@statnews.com.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy